N-C16-Deoxysphinganine is a biochemical reagent.

PSTC is a potent, selective Nrf2 activator with pEC50 of 7.7 (inducing of NQO1 specific enzyme activity).PSTC induces Nrf2 nuclear translocation, Nrf2-regulated gene expression, and downstream signaling events, including induction of NAD(P)H:NQO1 enzyme activity and heme oxygenase-1 protein expression, in an Nrf2-dependent manner.PSTC does not inhibit IL-1β-induced NF-κB translocation or insulin-induced S6 phosphorylation in human cells.PSTC restores oxidant (tert-butyl hydroperoxide) induced glutathione depletion in vitro and in vivo models of pulmonary oxidative stress.

MitoTracker Green FM is a green-fluorescent dye that can selectively accumulate in the mitochondrial matrix. MitoTracker Green FM covalently binds to mitochondrial proteins by reacting with free thiol groups of cysteine residues.

DSPE-PEG14-COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

DMG-PEG2000-Biotin is a synthetic amphiphilic molecule composed of dimyristoyl glycerol (DMG), polyethylene glycol (PEG2000), and biotin functionalities. It is commonly employed in biomedical research for surface modification of lipid-based delivery platforms, such as lipid nanoparticles (LNPs) and liposomes. The PEG moiety enhances colloidal stability, prolongs circulation time, and reduces rapid clearance in vivo. The biotin termination facilitates conjugation to streptavidin-tagged biomolecules, exploiting the highly specific biotin-streptavidin interaction. Thus, DMG-PEG2000-Biotin is valuable for drug-delivery optimization, targeted therapeutic approaches, and in vitro diagnostic assay development.

Thiol-PEG2000-DMG is a phospholipid polyPEG which can be used to prepare liposomes or nanoparticles. The terminal thiol group reacts with maleimide, OPSS, vinylsulfone and transition metal surfaces including gold, silver, etc.

DMG-PEG2000-OH is a PEG derivative that can be used to construct drug delivery vehicles.

DMG-PEG2000-SH is a PEG derivative that can be used to construct drug delivery vehicles.

DMG-PEG2000-TCO offer the ability to easily conjugate to specific biomolecules via metal free click chemistry to tetrazines. By changing the PEG length, one can change the micelle size, immunological safety, and change the drug release rate.

DMG-PEG2000-NHS is a PEG derivative that can be used in various biomedical applications, such as the construction of drug delivery systems (siRNA delivery liposomes, lipid nanoparticle, etc.). The active ester (NHS) can react with an amino group (-NH2) to form a stable amide bond, which can be used as a linker in a bioconjugation strategy to modify amino-linked peptide proteins as well as other small molecules.

AGPS-IN-1a is a potent inhibitor of the ether lipid-generating enzyme alkyl-glycerone phosphate synthase (AGPS), selectively lowers ether lipid levels in several types of human cancer cells and impairs their cellular survival and migration..

Lipid 11 is the optimal ionizable lipid disclosed by Liberate Bio, Inc. in patent WO2025/250730 A1, which can significantly improve the delivery efficiency of nucleic acid drugs to extrahepatic tissues including bone marrow, spleen and muscle, with excellent in vivo stability and safety.

DEA‑14‑DAP is a novel ionizable cationic SORT lipid. As a key component for central nervous system targeting, it enables lipid nanoparticles (LNPs) to specifically target microglia, significantly improving the delivery efficiency and cellular selectivity of nucleic acid drugs in the brain.

AMXT-1501 tetrahydrochloride (AMXT 1501, AMXT1501) is a novel potent polyamine transport inhibitor, synergistically reduces cell viability in NB cells in combination with DFMO.

(S)-IBD3540 is a potent, gut-restricted and orally active small molecule glutamate carboxypeptidase II (GCPII) inhibitor with IC50 of 4 nM, demonstrates anti-colitis activity in both acute and chronic mouse colitis models.

A novel small molecule disruptor of HuR-mRNA interaction with Ki of 350 nM.

LIPID168(pKa ~6.5) ​​ is an optimized ionizable lipid engineered for in vivo mRNA delivery to hematopoietic stem cells (HSCs) in bone marrow. Developed by ​​Yoltech Therapeutics​​ through high-throughput screening of lipid libraries, it features a ​​diethylamino head group​​ and a tailored hydrophobic tail structure that enables antibody-free targeting. When Lipid 168 was formulated into lipid nanoparticles (LNPs), it achieved ​​48.5% base editing efficiency​​ in bone marrow cells —surpassing benchmarks like LIPID-028 (19.7%)—and reduced off-target liver editing from 71% to 19% by incorporating ​​miR-122 target sequences​​. In humanized β-thalassemia models, LNP 168 delivered ABE8e mRNA/sgRNA to patient-derived HSCs, yielding ​​42.6% editing at the HBG promoter​​, reactivating fetal hemoglobin (γ-globin) and rescuing erythroid defects . Its bone marrow specificity is driven by a unique ​​protein corona​​ enriched in albumin, fibronectin, and fibrinogen . Safety studies confirmed transient immune responses and no cumulative toxicity . LIPID-168 represents a promising non-viral platform for curative gene therapies in blood disorders.

EB-Lipid is an innovatively engineered ionizable lipid designed to replace conventional PEG-lipid in mRNA vaccine formulations. Its structure comprises three key components: an Evans Blue-derived headgroup with high affinity for albumin, a tetraethylene glycol linker that enhances colloidal stability, and dual oleate tails for anchoring into lipid bilayers. This molecular design enables EB-Lipid to actively recruit endogenous albumin, forming an albumin-rich protein corona on the surface of lipid nanoparticles (LNPs). Following intramuscular administration, these albumin-bound EB-LNPs are preferentially transported through lymphatic vessels rather than entering the bloodstream, thereby avoiding hepatic accumulation and associated hepatotoxicity risks.Experimental data demonstrate that EB-LNPs achieve significantly higher accumulation in lymph nodes, where they are efficiently internalized by dendritic cells via albumin receptor-mediated endocytosis (e.g., gp60). This process enhances antigen presentation and activates robust cellular and humoral immune responses. In both tumor models (B16-OVA and HPV-associated) and infectious disease models (H1N1 and SARS-CoV-2 Omicron), EB-LNP-based mRNA vaccines elicited potent cytotoxic T-cell activation and durable neutralizing antibody production at low doses. Unlike traditional PEG-LNPs, EB-LNPs show minimal liver distribution, reduced immunogenicity, and improved safety profiles after repeated administrations.By leveraging albumin’s natural trafficking pathway, EB-Lipid represents a transformative delivery platform that combines targeted lymph node delivery with enhanced biosafety, positioning it as a promising candidate for next-generation mRNA vaccines and therapeutics.

AA76-lipid is a dipeptide-modified ionizable lipid, engineered with an arginine-histidine motif, that constitutes the core of the pancreatic-targeted AH-LNP delivery platform. Its chemical architecture, characterized by an externally positioned and C-terminally modified arginine residue, was identified through systematic screening as the optimal structure for function. Upon intraperitoneal administration, AH-LNPs formulated with this lipid interact with proteins in the peritoneal fluid, undergoing dynamic assembly into significantly larger complexes. This substantial increase in size (from ~100 nm to over 360 nm) exploits a physical targeting principle termed the Capsule-filter-mediated pancreatic targeting (CAMP) mechanism. Large particles are selectively filtered out by the dense capsules of other abdominal organs, leading to preferential enrichment in the capsule-deficient pancreas. Concurrently, the arginine-histidine motif directs the formation of a distinct protein corona enriched with apolipoproteins (e.g., APOE, APOB-100), which mimics very-low-density lipoprotein (VLDL). This corona enables efficient cellular internalization primarily into pancreatic stromal cells via VLDL receptor (VLDLR)-mediated endocytosis, known as the VMP pathway. The synergistic integration of the physical CAMP targeting and the biological VMP uptake mechanisms empowers AA76-lipid-based AH-LNPs to achieve highly specific, potent, and sustained mRNA delivery and gene editing within the pancreas across multiple species, demonstrating exceptional therapeutic efficacy in models of both autoimmune pancreatitis and pancreatic cancer.

Camonsertib is a potent ATR inhibitor. ATR inhibitor 4 has antitumor activity.

SAINT-2 is a cationic lipid with gene transfection activity and is a pyridyl lipid analog. Molecular membranes prepared by SAINT-2 can interact with plasmids to form lipid complexes. After the complex is taken up by cells, the plasmid dissociates from the lipid complex under the action of DOPE and the plasmid translocates across the endosome and/or nuclear membrane. Thus, SAINT-2 effectively transfers small oligonucleotides into cells。

DMT7 (pKa 6.5) is an ionizable cationic lipid engineered for co-delivery of mRNA and immunomodulators via LNPs. In 4T1 breast cancer metastasis models, DMT7 LNPs carrying IL-12 mRNA and STING agonist MSA-2 significantly reduce tumor burden and pulmonary metastases while modulating T cell populations. The formulation demonstrates broad immunotherapeutic effects in melanoma models, shifting tumor macrophages toward the M1 phenotype, reducing Tregs, and elevating pro-inflammatory cytokines (IL-12, IL-2, TNF-α, IFN-γ).

7-1 lipid represents a novel ionizable cationic compound designed for nucleic acid delivery applications.

DOIC is a cationic lipid that can be used for RNA vaccines.

DMDHP ((±)-Dimyristoyl-2,3-dimethylhydroxypropylamine) is a cationic lipid with a polar head group containing a dihydroxy group. DMDHP exhibits superior transfection efficiency and lower toxicity at high DNA doses in mouse intrapulmonary transfection model. DMDHP is commonly used for gene delivery.

APL-719 is a cationic lipid that can be used to synthesize lipid nanoparticles for drug delivery.

Lipid 29d is an ionizable lipid containing a thiophene moiety (Thio-lipid) for mRNA delivery. Lipid 29d enables LNPs to transfect the lung and spleen.

MIC1 is a set of multi-charged lipids with four tertiary amino nitrogen atoms (4N4T) which could be constructed and applied to form novel lipid nanoparticles. 4N4T-LNPs based on MIC1 exhibit much higher mRNA translation efficiency than the approved SM-102-LNPs. 4N4T-LNPs are successfully applied to DS mRNA vaccine and the vaccines worked well against SARS-CoV-2 and its variants, including Delta and Omicron.

Lipid 1 HG3 serves as a key component in LNPs specifically engineered for in vivo delivery of closed-end DNA (ceDNA), demonstrating efficient nucleic acid encapsulation and targeted release capabilities.